The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy

Molecular Medicine Today

Volumn 4, Issue 12, 1998, Pages 540-549

  López Larrea, Carlos ^a   González, Segundo ^b   Martínez Borra, Jesús ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN;

ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTATION; GENETIC POLYMORPHISM; HLA SYSTEM; NONHUMAN; REACTIVE ARTHRITIS; REVIEW; SPONDYLOARTHROPATHY;

ANIMALS; ANTIGEN PRESENTATION; ARTHRITIS, REACTIVE; HLA-B27 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR MIMICRY; POLYMORPHISM, GENETIC; SPONDYLITIS, ANKYLOSING;

BACTERIA (MICROORGANISMS); RODENTIA;

EID: 0344835943     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01375-6     Document Type: Review

References (49)

1. Calin, C. (1998) Terminology, introduction, diagnostic criteria, and overview, in The Spondylarthritides (Calin, A. and Taurog, J.D., eds), pp. 1-15, Oxford University Press.
2. Espinoza, L.R. and Cuellar, M.L. (1997) Clinical aspects of the spondyloarthropathies, in HLA-B27 in The Development of Spondyloarthropathies (López-Larrea, C., ed.), pp. 1-16, Landes Austin.
3. Brewerton D.A.et al. Ankylosing spondylitis and HL-A 27. Lancet. 1:1973;904-907.
4. Schlosstein L.et al. High association of an HLA antigen, W27, with ankylosing spondylitis. New Engl. J. Med. 288:1973;704-706.
5. Khan, M.A. (1997) Prevalence of HLA-B27 in world populations, in HLA-B27 in The Development of Spondyloarthropathies (López-Larrea, C., ed.), pp. 95-112, Landes Austin.
6. Braun J.et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 41:1998;58-67.
7. Brown M.A.et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA and the environment. Arthritis Rheum. 40:1997;1823-1828.
8. Brown M.A.et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum. 41:1998;588-595.
9. Taurog, J.D. (1988) HLA-B27 subtypes, disease susceptibility, and peptide binding specificity, in The Spondylarthritides (Calin, A. and Taurog, J.D., eds), pp. 267-273, Oxford University Press.
10. Madden D.R.et al. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell. 70:1992;1035-1048.
11. González-Roces S.et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens. 49:1997;116-123.
12. D'Amato M.et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur. J. Immunol. 25:1995;3199-3201.
13. López de Castro J.A. The pathogenetic role of HLA-B27 in chronic arthritis. Curr. Opin. Immunol. 10:1998;59-66.
14. López-Larrea C.et al. HLA-B27 subtypes in Asian patiens with ankylosing spondylitis. Evidence for new associations. Tissue Antigens. 45:1995;169-176.
15. Fiorilo M.T., Greco G., Sorrentino R. The Asp116-His116 substitution in a novel HLA-B27 subtype influences the acceptance of the peptide C-terminal anchor. Immunogenetics. 41:1995;38-39.
16. López-Larrea C., Gonzalez-Roces S., Alvarez V. HLA-B27 structure, function, and disease association. Curr. Opin. Rheumatol. 8:1996;296-308.
17. Galocha B.et al. Binding of peptides naturally presented by HLA-B27 to the diffentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. Tissue Antigens. 48:1996;509-518.
18. García F., Marina A., López de Castro J.A. Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated with ankylosing spondylitis. Tissue Antigens. 49:1997;215-221.
19. Tieng V.et al. HLA-B27 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes. Immunogenetics. 47:1997;103-105.
20. Aho K., Leirisalo-Repo M., Repo H. Reactive arthritis. Clin. Rheum. Dis. 11:1985;25-40.
21. Hermann E.et al. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet. 342:1993;646-650.
22. Uksila, J., Gripenberg-Lerche, C. and Toivanen, P. (1997) The role of environmental factors and HLA-B27, in HLA-B27 in The Development of Spondyloarthropathies (López-Larrea, C., ed.), pp. 167-181, Landes Austin.
23. MacLaren N.K., Atkinson M.A. Insulin-dependent diabetes mellitus: the hypothesis of molecular mimicry between islet cell antigens and microorganisms. Mol. Med. Today. 3:1997;76-83.
24. Gao X.M., Wordsworth P., McMichael A. Collagen-specific cytotoxic T lymphocyte responses in patients with ankylosing spondylitis and reactive arthritis. Eur. J. Immunol. 24:1994;1665-1670.
25. Hermann E.et al. HLA-B27 derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis. Arthritis Rheum. 40:1997;2047-2054.
26. 2m: An animal model of HLA-B27-associated human disorders. Cell. 63:1990;1099-1112.
27. Taurog J.D.et al. The germ free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med. 180:1994;2359-2364.
28. Breban M.et al. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J. Exp. Med. 178:1993;1607-1616.
29. Breban M.et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J. Immunol. 157:1996;794-803.
30. Zhou M.et al. The specificity of peptides bound to human histocompatibility antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. J. Exp. Med. 188:1998;877-886.
31. Ugrinovic S.et al. A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. J. Immunol. 159:1997;5715-5723.
32. Daser A., Urlaub H., Henklein P. HLA-B27 binding peptides derived from the 57kd heat shock protein of Chlamydia trachomatis: novel insights into the peptide binding rules. Mol. Immunol. 31:1994;331-336.
33. Probst P.et al. Identification of the Yersinia enterocolitica urease β subunit as a target antigen for human synovial T lymphocytes in reactive arthritis. Infect. Immun. 61:1993;4507-4509.
34. Raybourne, R.B. et al. (1997) The role of peptides in the recognition of HLA-B27 by cytotoxic T-cells and by antibodies, with special emphasis on arthritis patients, in HLA-B27 in The Development of Spondyloarthropathies (López-Larrea, C., ed.), pp. 197-215, Landes Austin.
35. Scofield R.H.et al. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: Implications for spondyloarthropathies. Lancet. 345:1995;1542-1544.
36. García F.et al. HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. Tissue Antigens. 49:1997;23-28.
37. 2-microglobulin: a model of human spondylarthropathies. J. Exp. Med. 182:1995;1153-1158.
38. Khare S.D.et al. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: A direct role for B27 heavy chains and not B27-derived peptides. J. Immunol. 160:1998;101-106.
39. Parham P. Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated arthritis. Immunol. Rev. 154:1996;137-154.
40. Davenport M.P. The promiscuous B27 hypothesis. Lancet. 346:1995;500-501.
41. Wildner G., Thurau S.R. Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. Eur. J. Immunol. 24:1994;2579-2585.
42. Wuorela M.et al. Yersinia enterocolitica serotype O:3 alters the expression of serologic HLA-B27 epitopes on human monocytes. Infect. Immun. 65:1997;2060-2066.
43. Laitio P.et al. HLA-B27 modulates intracellular survival of salmonella enteritidis in human monocytic cells. Eur. J. Immunol. 27:1997;1331-1338.
44. Virtala M., Kirveskari J., Granfors K. HLA-B27 modulates the survival of Salmonella enteritidis in transfected L cells, possibly by impaired nitric oxide production. Infect. Immun. 65:1997;4236-4242.
45. Whelan M.A., Archer J.R. Chemical reactivity of an HLA-B27 thiol group. Eur. J. Immunol. 23:1993;3278-3285.
46. Gao X.M.et al. Homocysteine modification of HLA antigens and its immunological consequences. Eur. J. Immunol. 26:1996;1443-1450.
47. Huang F.et al. Introduction of alternative splicing of HLA-B27 by bacterial invasion. Arthritis Rheum. 40:1997;694-703.
48. Zavazava N. Soluble HLA class I molecules: biological significance and clinical implications. Mol. Med. Today. 4:1998;116-121.
49. Weinreich S.S.et al. The role of MHC class I heterodimer expression in mouse ankylosing enthesopathy. Immunogenetics. 46:1997;35-40.